Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 4/20 | 0.85 |
| ▸ | YAP1 | P46937 | 1/20 | 0.85 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | EGFR | P00533 | 2/20 | 0.41 |
| ▸ | KDR | P35968 | 2/20 | 0.41 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.41 |
| ▸ | TLR2 | O60603 | 1/20 | 0.41 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.41 |
| ▸ | TNNI3K | Q59H18 | 8/20 | 0.40 |
| ▸ | BRAF | P15056 | 4/20 | 0.37 |
| ▸ | ALDH3A1 | P30838 | 1/20 | 0.36 |
| ▸ | IDH2 | P48735 | 1/20 | 0.36 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20779435 | 0.92 | TEAD1 (1.00) | TEAD1YAP1MAPTTSHRL3MBTL1 | |
| SCHEMBL29438871 | 0.92 | TEAD1 (1.00) | TEAD1YAP1MAPTTSHRL3MBTL1 | |
| SCHEMBL20766513 | 0.91 | TEAD1 (0.80) | TEAD1YAP1MAPTTSHRL3MBTL1 | |
| SCHEMBL25790400 | 0.90 | TEAD1 (0.72) | TEAD1YAP1MAPTTSHRL3MBTL1 | |
| SCHEMBL22718301 | 0.87 | TEAD1 (0.76) | TEAD1YAP1MAPTTSHRL3MBTL1 | |
| SCHEMBL22718256 | 0.87 | TEAD1 (0.80) | TEAD1YAP1MAPTTSHRL3MBTL1 | |
| SCHEMBL29438870 | 0.87 | TEAD1 (0.80) | TEAD1YAP1MAPTTSHRL3MBTL1 | |
| SCHEMBL29438928 | 0.87 | TEAD1 (0.76) | TEAD1YAP1MAPTTSHRL3MBTL1 | |
| SCHEMBL22718190 | 0.85 | TEAD1 (0.77) | TEAD1YAP1MAPTTSHRL3MBTL1 | |
| SCHEMBL22718294 | 0.85 | TEAD1 (0.74) | TEAD1YAP1MAPTTSHRL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| CN-111542315-B | Benzosulfonyl compounds | 维瓦斯治疗公司 | 2023-05-12 | — | — | CN | disclosed |
| EP-3691623-B1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS INC (US) | 2022-10-05 | — | — | EP | disclosed |
| US-11192865-B2 | Benzosulfonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-11192865-B2 | Benzosulfonyl compounds | VIVACE THERAPEUTICS, INC. (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2020-11-12 | — | — | US | disclosed |
| CN-111542315-A | Benzosulfonyl compounds | 维瓦斯治疗公司 | 2020-08-14 | — | — | CN | disclosed |
| EP-3691623-A1 | BENZOSULFONYL COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019040380-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
| WO-2019040380-A1 | BENZOSULFONYL COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2019-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11192865-B2 | Benzosulfonyl compounds | YAP1, TEAD2, TEAD1 | TEAD1 3/4885YAP1 1/4885MAPT 2341/4885 |
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | TEAD1 1/4885YAP1 9/4885MAPT 516/4885 |
| US-20200354325-A1 | BENZOSULFONYL COMPOUNDS | YAP1, TEAD2, TEAD1 | TEAD1 3/4885YAP1 1/4885MAPT 2341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.